Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Expansion of adipose tissue-derived stromal cells at "physiologic" hypoxia attenuates replicative senescence.

Ratushnyy A., Lobanova M., Buravkova LB.

Clinical Trial, published in Cell Biochem Funct (2017) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Cell Biochem Funct (2017)
Country
England
Reported sample size
—
Source database
PubMed
PMID
28589682
DOI
10.1002/cbf.3267

Abstract (original English)

Multipotent mesenchymal stromal cells are considered as a perspective tool in cell therapy and regenerative medicine. Unfortunately, autologous cell therapy does not always provide positive outcomes in elder donors, perhaps as a result of the alterations of stem cell compartments. The mechanisms of stem and progenitor cell senescence and the factors engaged are investigated intensively. In present paper, we elucidated the effects of tissue-related O 2 on morphology, functions, and transcriptomic profile of adipose tissue-derived stromal cells (ASCs) in replicative senescence in vitro model. Replicatively senescent ASCs at ambient (20%) O 2 (12-21 passages) demonstrated an increased average cell size, granularity, reactive oxygen species level, including anion superoxide, lysosomal compartment activity, and IL-6 production. Decreased ASC viability and proliferation, as well as the change of more than 10 senescence-associated gene expression were detected (IGF1, CDKN1C, ID1, CCND1, etc). Long-term ASC expansion at low O 2 (5%) revoked in part the replicative senescence-associated alterations.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueCell Culture TechniquesCell HypoxiaCells, CulturedCellular SenescenceFemaleGene Expression RegulationHumansMaleMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.